Index

abstracts 170
adverse drug experiences (ADEs) 19, 24, 27
adverse event reporting system (AERS) 27
advertising 5
alpha-1 norepinephrine (alpha-1) receptors 7
Alteplase 47
Alzheimer’s disease 10, 58, 73
amyloid hypothesis, target identification 37
amyloid precursor protein (APP) 37
animal models 40
autosomal dominant forms 10
cholinesterase inhibitors 11, 41
early treatments 179
gold standard tool 81
pre-clinical development 40–1
amines
biogenic amine theory, major depression 5
neurotransmitter systems 5
animal models in pre-clinical development 39–41
antibiotics 2
antibody affinity 47
antibody fragments 47
antidepressants evolution 4
history of drug development 4
new 4
TCAs, receptor binding profiles 7–8
antihypertensives, with ingestible wireless sensor 194
antipsychotics atypical 6, 10
human genome project 10
medical writing 163
ATP-dependent efflux pumps 46
authors’ submission toolkit 171
benzodiazepines 44
Best Pharmaceuticals for Children Act (BPCA, 2002) 17
beta-secretase see secretases
biologics, pre-clinical development 46–7
biomarker-based therapies
imatinib 79
trastuzumab 79
biomarkers
algorithms 87
data retrospective analysis 88
decision tree for research program 86
defined 65
drug rescue programs 88
endpoints 65
establishing specific biomarkers 66
methodologies 87
of non-response 82
optimal combinations 86
and personalized medicine 78
Phase I development 66
Phase II development 88
panels 85
pre-clinical development 48
rapid identification of treatment
effectiveness in major depression (BRITE-MD) 66
sensitivity 82
specificity 82
unbiased discovery methods 81
wireless health technology 196
bipolar disorder
cognition defects 181
functional milestone rates 178
regulatory guidance, clinical trials management 132
blood-brain barrier 45
endothelial cells, astrocytic projections 45
models 46
tight junctions 45
Center for Drug Evaluation and Research (CDER) 16
centuximab 88
chlorpromazine 3–4, 6, 33
binding affinity 6
vs. newer atypical antipsychotics 6
cholinesterase inhibitors, Alzheimer’s disease 11, 41
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 169
clinical trials information 169
abstracts 170
authors’ submission toolkit 171
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 169
continuing medical education (CME) 172
effect size measures 174
emerging and non-English-speaking markets 175
journals 170
on-line resources, standards and guidance 173
presenting results 174
promotional programming 174
publication 170
registration of clinical trials 169
regulatory documents 172
reviews 170
scientific meetings 170
clinical trials management at company level 127
appendix 145
case study 127
countries accepting placebo 138
country process for regulatory and ethical submissions 137
failure risk 127
key considerations 130
regulatory guidance 128
bipolar disorder 132
compliance improvement 129
depression 131
European Agency for Evaluation of Medicines (EMEA) 128
FDA 128
generalized anxiety disorder 133
key considerations 130
negative symptoms 128
placebo use 128
schizophrenia 130
special populations 129
study implementation 136
eligible patients 142, 144
investigators’ training 140
managing recruitment 141
measuring success 143
monitoring quality 143
recruitment rates 139
recruitment timelines and scenario planning 138
site selection 139
start-up phase 136
approval requirements 136
countries accepting placebo 138
country process 137
time to approval 137
see also Phase I trials
upfront planning 134
drug safety monitoring 135
feasibility study 135
global program 135
key areas 134
placebo arm acceptance 134
prevention of relapse studies 134
schizophrenia research activity 135
see also data collection; recruitment clonazepam 3
compliance failed CNS trials, wireless health technology 196
innovation 198
regulatory guidance 129
continuing medical education (CME) 172
continuous reassessment method (CRM) 63
data (and data analysis) 120–1
longitudinal analysis 121
missing at random (MAR) 121
missing completely at random (MCAR) 121
missing not at random (MNAR) 121
data collection project marketing tool kit 152
depression biogenic amine theory 5
major depressive disorder response rates in clinical trials 120
statistics issues 121
rapid identification of treatment effectiveness in major depression (BRITE-MD) 66
regulatory guidance, clinical trials management 131
sequenced treatment alternatives to relieve depression (STAR*D) project 93
direct-to-patient trials 197
drug development, learn and confirm phases 57
drugs (cont.)
development timeline 18
discovery 39
disruptive technologies 192, 197
drug-drug interaction 71
early drugs 3, 67
new drug application (NDA) 20, 26
reference listed drug (RLD) 26
rescue programs, biomarker data retrospective analysis 88
small molecules as CNS drug candidates 45
wireless health technology 194
Durham-Humphrey Amendment (1951) 16
eCTD format, regulatory issues 21
electroencephalography (EEG) 49
emerging and non-English-speaking markets 175
endophenotypes 49
ethical issues 89
anonymity of patient 89
data fortresses 89
informed consent forms (ICFs) 89
European Agency for Evaluation of Medicines (EMEA), regulatory guidance 128
event-related potentials (ERPs) 49
extrapyramidal symptoms, medical writing 164
fibin 47
Final Pediatric Rule (1998) 17
Food and Drug Administration (FDA)
Amendments Act (FDAAA, 2007) 17, 28
FDA Guidelines 15
Modernization Act (FDAMA 1997) 16
regulatory guidance 128
Food, Drug, and Cosmetic Act (FD&C Act 1938) 15, 22
fragment-based approaches, lead generation 43
functional magnetic resonance imaging (fMRI) 49
G-protein-coupled antagonists 75
G-protein-coupled receptors 34, 42
agonist binding 43
venus fly trap mechanism 43
GABA, fast inhibitory synaptic interactions 44
GABA receptor 44
GABA_A receptor 44
GABA_B receptor 36
GE V-scan device 193
generalized anxiety disorder (GAD), regulatory guidance 133
genomics
Phase II development 84
Good Laboratory Practice (GLP) regulations 18
Guidance for Industry, non-inferiority clinical trials 23
haloperidol 6
binding affinity 6 vs. newer atypical antipsychotics 6
Her2Neu 79
histamine-1 (H-1) 7
history of drug development advertising war 5
Alzheimer’s disease 10
amine neurotransmitter systems 5
antibiotic pharmacology 2
antidepressants 4
biogenic amine theory, major depression 5
blockbusters 1
eye drugs 3
human genome project 9
receptor binding affinity 6
receptor binding profiles 7–8
5-HT transporter (5-HTT) 50
human genome project 9
atypical antipsychotics 10
blockbuster model 9
cholesterase inhibitors 10
receptor binding profile of TCAs, SSRIs, and SNRIs 7–8
SNRIs, SSRIs 10
hyperprolactinemia, medical writing 164
ICH E3 Outline for Clinical Study Reports (1996) 157
imatinib, Phase II development 79
industry-funded trials see clinical trials management at site level
informed consent forms (ICFs) 89
innovation see disruptive technologies driving innovation
interferon-beta recombinant proteins 47
internet
clinical trial information, standards and guidance 173
ion channels 44
ligand gated 44
voltage gated 44
journals 170
Kefauver-Harris Amendment, regulatory issues 16
kinases 36
labeling 24–5
lead compounds
beta-secretase 42
discovery and refinement 41
drugability 41–2
fragment-based approaches 43
generation 41
high throughput screening technologies 42
ligand-gated ion channel family 36
magnetic resonance imaging (MRI) 49
magnetoencephalography (MEG) 49
marketing, recruitment to clinical trials 150
MATRICS consensus cognitive battery, schizophrenia 180
MATRICS project, schizophrenia 183
maximum tolerated single dose (MTD) 56, 60
Phase I trials 56, 60
medical writing 156
antidepressants 165
antipsychotics 163
efficacy considerations 161
efficacy measures 162
examples 156
future trends 165
ICH E3 Outline for Clinical Study Reports (1996) 157
measures employed in CNS studies 160
quality of life and safety measures 163
safety considerations 161
melanocyte concentrating hormone MCH-1 antagonists 35
MCH-1 receptor 34
metabolic syndrome, medical writing 164
minimum effective dose (MED) 97
mixed-effects model for repeated measures (MMRM) 120
monoamine reuptake inhibitors 33
monoamine transporter gene, polymorphism 79
monoclonal antibodies (MAbs) 46
MRP transporters 46
multiple ascending dose (MAD) study 55
PK and PD multiple doses of NME 57
multiple sclerosis 47
muscarinic-1 acetylcholine (M-1) 7
neuroleptic malignant syndrome, medical writing 164
new drug application (NDA) 20, 26
efficacy evaluation 22
generic drug approval process 14, 26
labeling 24–5
safety evaluation 23
NMDA antagonists 41
non-English-speaking markets 175
novel molecular entities (NMEs) 20, 55
nuclear hormone receptors 36
olanzepine, binding affinity 6
omics technologies 84
P-glycoprotein (PGP) 46
panitumab, Phase II development 88
Parkinson’s disease 36
gold standard tool 81
patent term restoration 16
Pediatric Research Equity Act (PREA, 2003) 17
phage 47
pharmacodynamics (PD) 56
pharmacogenomic data submissions (2005) 29
pharmacokinetic-pharmacodynamic (PKPD) model 71
pharmacokinetics (PK) 56, 59
half-life (t1/2), dose frequency 76
Phase I trials 55
adaptive designs 64
allocation rule 64
decision rule 64
determining optimal dose 65
first-in-human studies 65
response adaptive dose-ranging study designs 65
sampling rule 64
stopping rule 64
Alzheimer’s disease 58
cancer patients 60
continuous reassessment method (CRM) 63
optimal combinations of markers 86
biomarker panels 85
decision tree for research program 86
sufficient conditions 61
escalation scheme 56
lack of progress 58
late Phase I vs. early Phase II studies 57
male volunteers 60
maximum tolerated single dose (MTD) 56, 60
multiple ascending dose (MAD) study 55, 57
novel molecular entities (NMEs) 55
pharmacodynamics 56
pharmacokinetics 56
profile in healthy volunteers vs. participants 59
tolerability 60
positive and negative syndrome scale (PANSS) 59
single ascending dose (SAD) study 55–6
study implementation approval requirements 136
countries accepting placebo 138
country process 137
start-up phase 136
time to approval 137
target modulation 63
therapeutic index (TI) 63
traditional approach and challenges 59
see also biomarkers;
clinical trials management at company level and clinical trials management at site level
Phase II development 70
Alzheimer’s disease efficacy study 73
gold standard tool 81
biomarker data retrospective analysis 88
centuximab 88
drug rescue programs 88
panitumab 88
biomarker panels 85
decision tree for research program 86
optimal combinations of markers 86
biomarkers 87
algorithms 87
measurement technologies, MRM 85
Phase II development (cont.)
of non-response and personalized
medicine
sensitivity
specificity
therapies, imatinib, trastuzumab
unbiased discovery methods
centuximab
combining or skipping phases

dose frequency pharmacokinetic half-life ($t_{1/2}$)
dose selection
dose-response curve
drug-drug interaction
efficacy measure
effect size
signals vs. placebo
ethical issues
G-protein-coupled antagonists
HER2Neu
in vivo receptor occupancy
mechanistic hypothesis
number and selection of clinical study sites
omics approach
technologies
proteomic and genomic
79, 84
single nucleotide polymorphisms (SNPs)
personalized medicines and Phase II biomarkers
pharmacokinetic pharmacodynamic (PKPD) model
Phase Ia and Phase II decision making
Phase IIb efficacy
dose-response curve characterization
polymorphism of monoamine transporter gene
preparation
proof of concept (POC)
QTc prolongation
quantitative measures
randomization, blinding, active and placebo controls
regulatory issues
selection of indication
single nucleotide polymorphisms (SNPs)
 specimen collection and storage
therapeutic index (TI)
translatable proof of mechanism
validation
N-fold approach
see also biomarkers
Phase III development
comparators
efficacy, placebo response vs. active drug
placebo response
dose selection
minimum effective dose (MED)
endpoints
comparative efficacy
patient-reported outcomes (PROs)
initiation
safety
statistics issues
study populations
inclusion/exclusion criteria
insufficient generalizability
selection of patients
success rate, vs. Phase II
power and alpha level
tolerability
phenothiazines
Physician’s Labeling Rule (PLR)
placebo response
control
statistics issues
countries accepting placebo
upfront planning, placebo arm acceptance
use/regulatory guidance
positive and negative syndrome scale (PANSS)
 positron emission tomography (PET)
post-marketing commitment (PMC)
post-marketing drug regulation
potassium channels
preclinical development
animal models
Alzheimer’s disease
behavioral effects
secretase inhibitors
validity
beta-secretase
biologics as CNS drugs
Alteplase
antibody affinity
antibody fragments
fibrin
interferon-beta recombinant proteins
monoclonal antibodies (MAbs)
multiple sclerosis
phase
recombinant proteins
ribosome display
streptokinase
thrombolitics, stroke treatment
tissue plasminogen activator (tPA)
biomarkers
new developments
drug discovery process
four phases
target number and diversity
G-protein-coupled receptors
glutamate hypothesis, schizophrenia
validity
secretases in Alzheimer’s disease
small molecules as CNS drug candidates
<table>
<thead>
<tr>
<th>ATP-dependent efflux pumps</th>
<th>46</th>
</tr>
</thead>
<tbody>
<tr>
<td>blood-brain barrier models</td>
<td>46</td>
</tr>
<tr>
<td>blood-brain barrier lipophilicity</td>
<td>46</td>
</tr>
<tr>
<td>MRP transporters</td>
<td>46</td>
</tr>
<tr>
<td>P-glycoprotein (PGP)</td>
<td>46</td>
</tr>
<tr>
<td>pH trapping</td>
<td>46</td>
</tr>
<tr>
<td>target class approach</td>
<td>34–5</td>
</tr>
<tr>
<td>dopamine neurons</td>
<td>42</td>
</tr>
<tr>
<td>G-protein-coupled receptors</td>
<td>34</td>
</tr>
<tr>
<td>GABA&lt;sub&gt;B&lt;/sub&gt; receptor</td>
<td>36</td>
</tr>
<tr>
<td>kinases</td>
<td>36</td>
</tr>
<tr>
<td>ligand-gated ion channel family</td>
<td>36</td>
</tr>
<tr>
<td>MCH-1 antagonists</td>
<td>35</td>
</tr>
<tr>
<td>melanocyte concentrating hormone (MCH)</td>
<td>34</td>
</tr>
<tr>
<td>nuclear hormone receptors</td>
<td>36</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>36</td>
</tr>
<tr>
<td>potassium channels</td>
<td>36</td>
</tr>
<tr>
<td>SLC-1 in recombinant systems</td>
<td>35</td>
</tr>
<tr>
<td>synaptic transmission</td>
<td>34</td>
</tr>
<tr>
<td>voltage-gated ion channels</td>
<td>36</td>
</tr>
<tr>
<td>target discovery</td>
<td>34</td>
</tr>
<tr>
<td>target identification</td>
<td>37</td>
</tr>
<tr>
<td>target validation</td>
<td>38, 41</td>
</tr>
<tr>
<td>translational research, defined</td>
<td>48</td>
</tr>
<tr>
<td>prepulse inhibition (PPI)</td>
<td>50</td>
</tr>
<tr>
<td>Prescription Drug User Fee Act (PDUFA, 1992)</td>
<td>16</td>
</tr>
<tr>
<td>presenilin</td>
<td>37</td>
</tr>
<tr>
<td>promotional programming</td>
<td>174</td>
</tr>
<tr>
<td>proof of concept (POC)</td>
<td>48, 71</td>
</tr>
<tr>
<td>proof of mechanism (POM)</td>
<td>48, 72</td>
</tr>
<tr>
<td>proof of safety (POS)</td>
<td>48</td>
</tr>
<tr>
<td>proteomics</td>
<td>79</td>
</tr>
<tr>
<td>Phase II development</td>
<td>84</td>
</tr>
<tr>
<td>publication of trial information</td>
<td>170</td>
</tr>
<tr>
<td>QTc prolongation</td>
<td>74</td>
</tr>
<tr>
<td>medical writing</td>
<td>164</td>
</tr>
<tr>
<td>Phase II development</td>
<td>74</td>
</tr>
<tr>
<td>quality of life, and safety measures</td>
<td>163</td>
</tr>
<tr>
<td>quetiapine, binding affinity</td>
<td>6</td>
</tr>
<tr>
<td>receptor binding profiles, TCAs</td>
<td>7–8</td>
</tr>
<tr>
<td>recombinant proteins</td>
<td>46</td>
</tr>
<tr>
<td>recombinant tPAs</td>
<td>47</td>
</tr>
<tr>
<td>recruitment to clinical trials</td>
<td>150</td>
</tr>
<tr>
<td>access to 151</td>
<td></td>
</tr>
<tr>
<td>marketing methods</td>
<td>150</td>
</tr>
<tr>
<td>per indication per region</td>
<td>145–6</td>
</tr>
<tr>
<td>rates</td>
<td>139</td>
</tr>
<tr>
<td>timelines and scenario planning</td>
<td>138</td>
</tr>
<tr>
<td>unique recruiting sites</td>
<td>145</td>
</tr>
<tr>
<td>word of mouth as referral tool</td>
<td>151</td>
</tr>
<tr>
<td>reference listed drug (RLD)</td>
<td>26</td>
</tr>
<tr>
<td>registration of clinical trials</td>
<td>169</td>
</tr>
<tr>
<td>regulatory documents</td>
<td>172</td>
</tr>
<tr>
<td>regulatory guidance</td>
<td>129</td>
</tr>
<tr>
<td>bipolar disorder</td>
<td>132</td>
</tr>
<tr>
<td>clinical trials management at company level</td>
<td>128</td>
</tr>
<tr>
<td>compliance improvement</td>
<td>129</td>
</tr>
<tr>
<td>Guidance for Industry</td>
<td>23</td>
</tr>
<tr>
<td>key considerations</td>
<td>130</td>
</tr>
<tr>
<td>negative symptoms</td>
<td>128</td>
</tr>
<tr>
<td>placebo use</td>
<td>128</td>
</tr>
<tr>
<td>schizophrenia</td>
<td>130</td>
</tr>
<tr>
<td>special populations</td>
<td>129</td>
</tr>
<tr>
<td>regulatory issues</td>
<td>14, 16</td>
</tr>
<tr>
<td>adverse drug experiences (ADEs)</td>
<td>19, 24</td>
</tr>
<tr>
<td>adverse event reporting system (AERS)</td>
<td>27</td>
</tr>
<tr>
<td>Amendments Act (FDAAA, 2007)</td>
<td>17, 28</td>
</tr>
<tr>
<td>approval letter</td>
<td>26</td>
</tr>
<tr>
<td>Best Pharmaceuticals for Children Act (BPCA, 2002)</td>
<td>17</td>
</tr>
<tr>
<td>Center for Drug Evaluation and Research (CDER)</td>
<td>16</td>
</tr>
<tr>
<td>clinical drug development process</td>
<td>18</td>
</tr>
<tr>
<td>contraindications</td>
<td>25</td>
</tr>
<tr>
<td>drug classification coding</td>
<td>20</td>
</tr>
<tr>
<td>drug development timeline</td>
<td>18</td>
</tr>
<tr>
<td>Drug Efficacy Study Implementation (DESI)</td>
<td>16</td>
</tr>
<tr>
<td>Drug Safety Oversight Board (2005)</td>
<td>28</td>
</tr>
<tr>
<td>Durham-Humphrey Amendment (1951)</td>
<td>16</td>
</tr>
<tr>
<td>eCTD format</td>
<td>21</td>
</tr>
<tr>
<td>elements to assure safe use (ETASU)</td>
<td>24</td>
</tr>
<tr>
<td>expanded access to treatment</td>
<td>20</td>
</tr>
<tr>
<td>FD&amp;C Act (1938)</td>
<td>15, 22</td>
</tr>
<tr>
<td>FDA Guidelines</td>
<td>15</td>
</tr>
<tr>
<td>Final Pediatric Rule (1998)</td>
<td>17</td>
</tr>
<tr>
<td>generic drug approval process</td>
<td>14, 26</td>
</tr>
<tr>
<td>Good Laboratory Practice (GLP) regulations</td>
<td>18</td>
</tr>
<tr>
<td>investigational new drug</td>
<td>17</td>
</tr>
<tr>
<td>Kefauver-Harris Amendment</td>
<td>16</td>
</tr>
<tr>
<td>labeling</td>
<td>24–5</td>
</tr>
<tr>
<td>MedWatch</td>
<td>27–8</td>
</tr>
<tr>
<td>new drug application (NDA)</td>
<td>20, 26</td>
</tr>
<tr>
<td>new molecular entity (NME)</td>
<td>20</td>
</tr>
<tr>
<td>patent term restoration</td>
<td>16</td>
</tr>
<tr>
<td>Pediatric Research Equity Act (PREA, 2003)</td>
<td>17</td>
</tr>
<tr>
<td>pharmacogenomic data submissions (2005)</td>
<td>29</td>
</tr>
<tr>
<td>Phase I</td>
<td>18</td>
</tr>
<tr>
<td>Phase II</td>
<td>19</td>
</tr>
<tr>
<td>Phase III</td>
<td>19</td>
</tr>
<tr>
<td>Physician’s Labeling Rule (PLR)</td>
<td>25</td>
</tr>
<tr>
<td>post-marketing commitment (PMC)</td>
<td>28</td>
</tr>
<tr>
<td>post-marketing drug regulation</td>
<td>27</td>
</tr>
<tr>
<td>post-marketing requirements (PMRs)</td>
<td>28</td>
</tr>
<tr>
<td>prescribing information</td>
<td>25</td>
</tr>
<tr>
<td>Prescription Drug User Fee Act (PDUFA, 1992)</td>
<td>26</td>
</tr>
<tr>
<td>reference listed drug (RLD)</td>
<td>16</td>
</tr>
<tr>
<td>risk evaluation and mitigation strategy (REMS)</td>
<td>17, 24</td>
</tr>
<tr>
<td>Safe Use Initiative</td>
<td>29</td>
</tr>
<tr>
<td>safety evaluation</td>
<td>23</td>
</tr>
<tr>
<td>Sentinel System</td>
<td>29</td>
</tr>
</tbody>
</table>
regulatory issues (cont.)
treatment INDs 20
warnings/precautions 25
REMOTE trial, disruptive technologies 197
research site 148
see also clinical trials management at site level
reverse pharmacology 33–4
chlorpromazine 33
dopamine D2 receptor antagonists 33
monoamine reuptake inhibitors 33
and multi-target agents 33–4
selective inhibitors of serotonin transporters (SSRIs) 33
serotonin-noradrenaline reuptake inhibitors (SNRIs) 33
reviews, clinical trial information 170
ribosome display 47
risk evaluation and mitigation strategy (REMS) 17, 24
risperidone, binding affinity 6
Safe Use initiative 29
safety
drug monitoring 135
Drug Safety Oversight Board (2005) 28
elements to assure safe use (ETASU) 24
evaluation, regulatory issues 23
medical writing 161
MedWatch Safety Alerts 28
Phase III development 98
proof of safety (POS) 48
and quality of life 163
surveillance, wireless health technology 196
schizophrenia
cognition impairments 177
ability score correlations 182–3
augmentation therapy 182
clinical trials management 135
clinical trials regulatory guidance 130, 135
clinical trials research activity per region 135
cognitive enhancement studies 185
compounds and mechanisms of action 185
drug interventions 179
drug interventions, results 184
drug pre-clinical development 139
drugs, enhancement research design 181
functional milestone rates 178
glutamate hypothesis 39
MATRICS consensus cognitive battery 180
MATRICS project 183
non-pharmacological interventions 185
placebo response 119
prediction of community activities 178
remediation 188
validation of co-primary measures 182
dosing 186–7
cognitive change 187
concurrent treatments 187
functional outcomes 187
magnitude of effect 187
scheduling 186
functional milestones 178
pre-clinical development 139
scientific meetings 170
secretases
Alzheimer’s disease 45
beta-secretase 45
gamma-secretase 37, 45
lead generation fragment-based approaches 43, 45
inhibitors 40
selective serotonin reuptake inhibitors (SSRIs) 33, 50, 79
human genome project 10
Phase II development 79
receptor binding profiles 7–8
Sentinel System 29
serotonin-noradrenaline reuptake inhibitors (SNRIs) 33
human genome project 10
signal detection
baseline observation carried forward (BOCF) 122
improvement 120
last observation carried forward (LOCF) 120
mixed-effects model for repeated measures (MMRM) 120
wireless health technology 195
single ascending dose (SAD) study design 55–6
single nucleotide polymorphisms (SNPs) 50, 84
Phase II 84
single photon emission computerized tomography (SPECT) 49
site see clinical trials management at site level
SLC-1 in recombinant systems 35
small molecules as CNS drug candidates 45
specimen collection and storage
blood specimens 82
collection tube type impact 83
long-term storage 83
standard operating procedures (SOPs) 82–3
temperature 83
standard operating procedures (SOPs), specimen collection 82–3
statistics issues 100
adaptive designs 105
clinically meaningful difference (CMD) 105
dose-response scenarios 105
fixed and adaptive clinical trial simulator (FACTS) software 106
secondary archtypes 105
two-stage 107
analytic road map 124
axes of development 101–2
dose-response 101
signal detection 102
baseline observation carried forward (BOCF) 122
design archetypes 100
false negative results 100
false positive results 100
historical data 113
last observation carried forward (LOCF) 120
longitudinal clinical trials 124
major depressive disorder 121
missing data and data analysis 120–1
longitudinal analysis 121
missing at random (MAR) 121
missing completely at random (MCAR) 121
observational and causal components 117–18
optimum for portfolio 104
outcomes
causal pathways 118
positive controls 111
probabilities 108, 110
Phase III
portfolio attributes 116
success rate vs. Phase II
power and alpha level 117
placebo response control 118, 120
baseline severity 119
patient expectation 119
schizophrenia 119
and signal detection 115
portfolio modeling and simulation 114
positive control 106
outcomes 109–11
portfolio perspective 109, 113
quantitative evaluation 107, 112
primary archetypes 102
fast-to-PoC 102
fast-to-registration 103
secondary archetypes 103
signal detection improvement 120
mixed-effects model for repeated measures (MMRM) 120
standard of care comparisons 111
streptokinase 47
stroke, thrombolytics 47
synaptic transmission 34
therapeutic index (TI)
Phase I trials 63
Phase II development 72
thioridazine 3
thrombolytics 47
tissue plasminogen activator (tPA) 47
translational research 48, 72
defined 48
tristuzumab, Phase II development 79
treatment INDs 20
validity
construct validity 40
face validity 40
predictive validity 40
voltage-gated ion channels 36
Waxman-Hatch act, regulatory issues 16
wireless health technology 192–4
biomarkers 196
clinical drug development 194
efficacy measures in trials 196
safety surveillance, post approval 196
signal detection 195
subject compliance and failed CNS trials 196
wireless technology for remote care and monitoring 193
world countries
accepting placebo 138
process for regulatory and ethical submissions 137
start-up phase, clinical trials management at company level 137
ziprasidone, binding affinity 6